Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy
BackgroundGlioblastoma (GBM) is the deadliest form of brain cancer, impacting both adults and children, marked by exceptionally high morbidity and mortality rates, even with current standard treatments such as surgery, radiation therapy, and chemotherapy. Therefore, there is a pressing need for new...
Saved in:
| Main Authors: | Julia Uffenorde, Mehran Hariri, Eleftherios Papalanis, Annika Staffas, Josefine Berg, Bo Stenerlöw, Hanna Berglund, Christer Malmberg, Diana Spiegelberg |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1451156/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
by: Anja Charlotte Lundgren Mortensen, et al.
Published: (2023-10-01) -
Author Correction: Combination therapy of tyrosine kinase inhibitor sorafenib with the HSP90 inhibitor onalespib as a novel treatment regimen for thyroid cancer
by: Anja Charlotte Lundgren Mortensen, et al.
Published: (2025-07-01) -
Editorial: Immune therapies in neurological disorders
by: Jie Pan
Published: (2025-05-01) -
Self-replicating recombinant virus-like particles of lentivirus proliferating in glioblastoma cells and normal human macrophages
by: Herman D. Moshkoff, et al.
Published: (2024-11-01) -
A Systematic Review of Nanoparticle-Mediated Ferroptosis in Glioma Therapy
by: Jing L, et al.
Published: (2025-05-01)